DK1740601T3 - Myosin-letkæde-kinase-inhibitorer og deres anvendelse - Google Patents

Myosin-letkæde-kinase-inhibitorer og deres anvendelse

Info

Publication number
DK1740601T3
DK1740601T3 DK05777465.5T DK05777465T DK1740601T3 DK 1740601 T3 DK1740601 T3 DK 1740601T3 DK 05777465 T DK05777465 T DK 05777465T DK 1740601 T3 DK1740601 T3 DK 1740601T3
Authority
DK
Denmark
Prior art keywords
light chain
kinase inhibitors
myosin light
chain kinase
myosin
Prior art date
Application number
DK05777465.5T
Other languages
English (en)
Inventor
Jerrold R Turner
Randall J Mrsny
Derek Mckay
Original Assignee
Univ Chicago
Univ Cardiff
Univ Mcmaster
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Chicago, Univ Cardiff, Univ Mcmaster filed Critical Univ Chicago
Application granted granted Critical
Publication of DK1740601T3 publication Critical patent/DK1740601T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK05777465.5T 2004-04-21 2005-04-21 Myosin-letkæde-kinase-inhibitorer og deres anvendelse DK1740601T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56431304P 2004-04-21 2004-04-21
PCT/US2005/013411 WO2005108416A2 (en) 2004-04-21 2005-04-21 Myosin light chain kinase inhibitors and their use

Publications (1)

Publication Number Publication Date
DK1740601T3 true DK1740601T3 (da) 2013-03-11

Family

ID=35320788

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05777465.5T DK1740601T3 (da) 2004-04-21 2005-04-21 Myosin-letkæde-kinase-inhibitorer og deres anvendelse

Country Status (9)

Country Link
US (2) US7585844B2 (da)
EP (1) EP1740601B1 (da)
JP (1) JP2008501640A (da)
CN (1) CN1997660A (da)
AU (1) AU2005241009A1 (da)
CA (1) CA2563508A1 (da)
DK (1) DK1740601T3 (da)
ES (1) ES2400567T3 (da)
WO (1) WO2005108416A2 (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2400567T3 (es) * 2004-04-21 2013-04-10 The University Of Chicago Inhibidores de cinasa de la cadena ligera de miosina y su uso
WO2008028085A2 (en) * 2006-08-30 2008-03-06 The Board Of Trustees Of The University Of Illinois Modulation of mlck-l expression and uses thereof
US8785374B2 (en) * 2007-10-19 2014-07-22 Alba Therapeutics Corporation Inhibitors of mammalian tight junction opening
GB0803352D0 (en) * 2008-02-22 2008-04-02 Ntnu Technology Transfer As Oligopeptidic compounds and uses thereof
CA2737774A1 (en) * 2008-09-19 2010-03-25 Henry Ford Health System Methods, systems, and compositions for calpain inhibition
ES2938049T3 (es) 2009-10-16 2023-04-04 Scripps Research Inst Inducción de células pluripotentes
RU2443710C1 (ru) * 2010-10-13 2012-02-27 Федеральное государственное учреждение "Российский кардиологический научно-производственный комплекс" Министерства здравоохранения и социального развития Российской Федерации (ФГУ "РКНПК" Минздравсоцразвития России) Циклический нонапептид, обладающий способностью ингибировать киназу легких цепей миозина
JP6182456B2 (ja) 2010-12-22 2017-08-23 フェイト セラピューティクス，インコーポレイテッド 単細胞選別のための細胞培養プラットホームおよびｉＰＳＣの再プログラミングの増強
EP3604499A1 (en) 2014-03-04 2020-02-05 Fate Therapeutics, Inc. Improved reprogramming methods and cell culture platforms
RU2592282C1 (ru) * 2015-06-19 2016-07-20 Федеральное государственное бюджетное учреждение "Российский кардиологический научно-производственный комплекс" Министерства здравоохранения Российской Федерации (ФГБУ "РКНПК" Минздрава России) Способ получения нонапептидов
US11441126B2 (en) 2015-10-16 2022-09-13 Fate Therapeutics, Inc. Platform for the induction and maintenance of ground state pluripotency
WO2017075573A1 (en) * 2015-10-29 2017-05-04 University Of Maryland, College Park Compositions and methods for inhibition of bacterial infections in human endocervix
WO2019210377A1 (en) * 2018-04-30 2019-11-07 L'oreal Bioactive peptides having high binding affinity to human muscular nicotinic acetylcholine receptor
CN111116756B (zh) * 2019-12-31 2021-08-10 山东第一医科大学(山东省医学科学院) 抑制lyn激酶引起的mlck激活的融合多肽及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL102964A0 (en) * 1991-08-26 1993-01-31 Cytel Corp Hla-restricted hepatitis b virus ctl epitopes
DE69231123T2 (de) 1992-03-25 2001-02-15 Immunogen Inc Konjugaten von Zell-bindender Mittel und Derivaten von CC-1065
US5336503A (en) 1992-03-31 1994-08-09 Daiichi Pharmaceutical Co., Ltd. Anti-peptic ulcer agent
NZ255041A (en) * 1992-07-13 1996-11-26 Bionebraska Inc Preparation of a recombinant single copy polypeptide or portion thereof modified with a terminal alpha amino carbon reactive group and reactive side chain groups involving biologically added protective groups
US20030203976A1 (en) 1993-07-19 2003-10-30 William L. Hunter Anti-angiogenic compositions and methods of use
US5891689A (en) 1994-04-12 1999-04-06 Innovir Laboratories, Inc. Heme-bearing microparticles for targeted delivery of drugs
DE69520044T2 (de) 1994-10-12 2001-06-13 Focal, Inc. Zielgerichte verabreichung mittels biologisch abbaubarer polymere
US5998580A (en) * 1995-10-13 1999-12-07 Fay; Frederick F. Photosensitive caged macromolecules
ATE229977T1 (de) * 1996-03-26 2003-01-15 Razvan T Radulescu Peptide mit antiproliferativen eigenschaften
US6172043B1 (en) 1997-01-10 2001-01-09 Massachusetts Institute Of Technology Treatments for neurotoxicity in Alzheimer's disease caused by β amyloid peptides
US6777388B1 (en) * 1998-08-21 2004-08-17 Clf Medical Technology Acceleration Program, Inc. Leptin-related peptides
US7049395B2 (en) * 2000-05-02 2006-05-23 Yale University Anti-inflammatory compounds and uses thereof
WO2002004482A1 (en) * 2000-07-07 2002-01-17 Panacea Pharmaceuticals, Inc. Methods for preventing neural tissue damage and for the treatment of alpha-synuclein diseases
US6673574B2 (en) 2000-11-30 2004-01-06 Unigene Laboratories Inc. Oral delivery of peptides using enzyme-cleavable membrane translocators
US7452877B2 (en) * 2002-03-15 2008-11-18 Rytek Methods for treating digestive functional pathologies
AU2003219327A1 (en) * 2002-04-17 2003-11-03 Medical Research Council Fp receptor antagonists or pgf2 alpha antagonists for treating menorrhagia
ES2400567T3 (es) * 2004-04-21 2013-04-10 The University Of Chicago Inhibidores de cinasa de la cadena ligera de miosina y su uso

Also Published As

Publication number Publication date
WO2005108416A2 (en) 2005-11-17
EP1740601B1 (en) 2012-12-05
US20050261196A1 (en) 2005-11-24
US7585844B2 (en) 2009-09-08
ES2400567T3 (es) 2013-04-10
EP1740601A2 (en) 2007-01-10
CN1997660A (zh) 2007-07-11
AU2005241009A1 (en) 2005-11-17
WO2005108416A3 (en) 2006-05-04
CA2563508A1 (en) 2005-11-17
US20100016242A1 (en) 2010-01-21
JP2008501640A (ja) 2008-01-24

Similar Documents

Publication Publication Date Title
DK1740601T3 (da) Myosin-letkæde-kinase-inhibitorer og deres anvendelse
DK1954140T3 (da) Glycerollevulinatketaler og deres anvendelse
NO20091423L (no) Pyrimidinderivater og deres anvendelse som kinaseinhibitorer
NO2017017I1 (no) umeklinidium og vilanterol
DK1713806T3 (da) Forbindelser og sammensætninger som proteinkinaseinhibitorer
NO20161397A1 (no) Ikke-nukleosidbaserte revers-transkriptase-inhibitorer
DK1499311T3 (da) Substituerede benzaboler og anvendelse deraf som RAF-kinaseinhibitorer
DK1732892T3 (da) Tetrahydrocarbazoler og derivater
DK1753748T3 (da) Prolinderivater og deres anvendelse som dipeptidyl-peptidase-IV-inhibitorer
DK1704145T3 (da) Selektive kinaseinhibitorer
DK1931645T3 (da) N-(3-aminoquinoxalin-2-yl)-sulfonamidderivater og deres anvendelse som inhibitorer af phosphatidylinositol-3-kinase
NO20085030L (no) Pyrrolopyrimidinforbindelser og deres anvendelser
DK1723128T3 (da) Heteroarylurinstoffer og deres anvendelse som glucokinaseaktivatorer
DK1841757T3 (da) Heteroaromatiske quinolin-forbindelser og deres anvendelse som PDE10-hæmmere
DK1592686T3 (da) Gyrase-inhibitorer og anvendelser deraf
ATE505471T1 (de) Azaindol-kinaseinhibitoren
DK1713805T3 (da) Kinaseinhibitorer
DE502005010369D1 (de) Nockenwellenversteller
DK1928457T3 (da) Quinoliner og deres terapeutiske anvendelse
DK2332909T3 (da) Hydroxybenzamidderivater og deres anvendelse som inhibitorer af hsp90
ATE423121T1 (de) Diphenylimidazopyrimidin- und -imidazolamine als b-sekretase-inhibitoren
DK1730146T3 (da) Azaindoler anvendelige som inhibitorer af JAK og andre proteinkinaser
DK1943243T3 (da) Kinase-inhibitorer
NO20084764L (no) Tioksantinderivater og deres anvendelse som MPO inhibitorer
DK1738044T3 (da) Nöglekombinationseelement i nögleråemne og nögle